| BIOMARIN PHAR. DL-,001 |
| USA |
| Gesundheit |
| US09061G1013 / 924801 |
| BM8 (Frankfurt) / BMRN (NASDAQ) |
| FRA:BM8, ETR:BM8, BM8:GR, NASDAQ:BMRN |
| - |
| https://www.biomarin.com/ |
|
BioMarin Pharmaceutical Inc. is a leading biotechnology company specializing in the development and commercialization of innovative therapies for rare genetic diseases. Established in 1997 and headqua..
>Volltext.. |
| 10446.33 Mio. EUR |
| 9708.66 Mio. EUR |
| 2617.86 Mio. EUR |
| 796.09 Mio. EUR |
| 441.6 Mio. EUR |
| 2.31 EUR |
| 518.63 Mio. EUR |
| 1060.79 Mio. EUR |
| 775.56 Mio. EUR |
| 1.85 |
| 6.57% |
| 53.21% |
| - |
| - |
| - |
| - |
| BIOMARIN |
| 24.02.26 |
|
||||
|